Aggarwal Sumit

President and CEO, Director, 10% OwnerEloxx Pharmaceuticals, Inc. (ELOX) · full profile →Form 4 · filed May 8, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
20
4 non-derivative · 16 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 28, 2026Option exercise(M)261K$0.15$39K1.7M
Jan 24, 2026Option exercise(M)15K1.4M
Sep 19, 2025Grant(A)1.0M$01.4M
Aug 14, 2025Option exercise(M)197K$0.00$20397K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 28, 2026Option exercise(M)261K$03.3M
Jan 24, 2026Option exercise(M)15K$015K
Sep 19, 2025Grant(A)3.6M$03.6M
Aug 14, 2025Option exercise(M)60K$00
Aug 14, 2025Option exercise(M)69K$00
Aug 14, 2025Option exercise(M)25K$00
Aug 14, 2025Option exercise(M)43K$00
Oct 16, 2024Disposed to issuer(D)69K0
Oct 16, 2024Grant(A)69K69K
Oct 16, 2024Disposed to issuer(D)43K0
Oct 16, 2024Grant(A)43K43K
Oct 16, 2024Disposed to issuer(D)36K0
Oct 16, 2024Grant(A)36K36K
Oct 16, 2024Disposed to issuer(D)25K0
Oct 16, 2024Grant(A)25K25K
Feb 6, 2022Grant(A)43K$043K

Transaction Codes

M
Option exercise / conversion
A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-214890) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.